Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01405885 · ClinicalTrials.gov registry record · Phase 1
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT01405885 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 116 participants.
The verdict
NCT01405885, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by electroporation in healthy adults
Interventions
- BIOLOGICAL INO-3605
- BIOLOGICAL INO-3609
- BIOLOGICAL INO-3401
- BIOLOGICAL INO-3605 AND INO-3609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01405885
The ClinicalTrials.gov registry entry for NCT01405885 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which INO-3605 is the first listed.
NCT01405885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01405885 about?
NCT01405885 is a clinical study titled "A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus". This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by electroporation in healthy adults
What is the current status of trial NCT01405885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2011-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01405885?
The interventions under investigation include: INO-3605 (BIOLOGICAL), INO-3609 (BIOLOGICAL), INO-3401 (BIOLOGICAL), INO-3605 AND INO-3609 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01405885?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.